MedPage Today7h
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Unanimously, Federal Trade Commission Issues Second Pounding of Big PBMs
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
New report accuses PBMs of driving up prescription drug costs
The Federal Trade Commission found Pharmacy Benefit Managers profited billions by raising the prices of "specialty drugs." ...
FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
STAT12h
Will PBM reform save pharmacies from closing?
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
Lawmaker may file bill to regulate PBMs: They’re managing the dollar
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
FTC says PBMs inflated prices
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
STAT7h
Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...